The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism
P M Clare1, R A Poorman, L C Kelley
1Department of Cell and Molecular Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007-4940, USA.
Abstract:
cdk2.cyclin E and cdk5.p25 are two members of the cyclin-dependent kinase family that are potential therapeutic targets for oncology and Alzheimer's disease, respectively. In this study we have investigated the mechanism for these enzymes. Kinases catalyze the transfer of phosphate from ATP to a protein acceptor, thus utilizing two substrates, ATP and the target protein. For a two-substrate reaction, possible kinetic mechanisms include: ping-pong, sequential random, or sequential ordered. To determine the kinetic mechanism of cdk2.GST-cyclin E and cdk5.GST-p25, kinase activity was measured in experiments in which concentrations of peptide and ATP substrates were varied in the presence of dead-end inhibitors. A peptide identical to the peptide substrate, but with a substitution of valine for the phosphoacceptor threonine, competed with substrate with a K(i) value of 0.6 mm. An aminopyrimidine, PNU 112455A, was identified in a screen for inhibitors of cdk2. Nonlinear least squares and Lineweaver-Burk analyses demonstrated that the inhibitor PNU 112455A was competitive with ATP with a K(i) value of 2 microm. In addition, a co-crystal of PNU 112455A with cdk2 showed that the inhibitor binds in the ATP binding pocket of the enzyme. Analysis of the inhibitor data demonstrated that both kinases use a sequential random mechanism, in which either ATP or peptide may bind first to the enzyme active site. For both kinases, the binding of the second substrate was shown to be anticooperative, in that the binding of the first substrate decreases the affinity of the second substrate. For cdk2.GST-cyclin E the kinetic parameters were determined to be K(m, ATP) = 3.6 +/- 1.0 microm, K(m, peptide) = 4.6 +/- 1.4 microm, and the anticooperativity factor, alpha = 130 +/- 44. For cdk5.GST-p25, the K(m, ATP) = 3.2 +/- 0.7 microm, K(m, peptide) = 1.6 +/- 0.3 microm, and alpha = 7.2 +/- 1.8.
Insights
Cyclin-dependent kinases (CDKs) like CDK2 and CDK5 are crucial drug targets. This study reveals both enzymes utilize a sequential random mechanism with anticooperative substrate binding, offering insights for therapeutic development.
Area of Science:
- Biochemistry
- Enzymology
- Molecular Biology
Background:
- Cyclin-dependent kinases (CDKs) are key regulators of cell cycle and neuronal function.
- CDK2-cyclin E and CDK5-p25 are implicated in cancer and Alzheimer's disease, respectively.
- Understanding their kinetic mechanisms is vital for targeted drug development.
Purpose of the Study:
- To elucidate the kinetic mechanisms of CDK2-cyclin E and CDK5-p25.
- To characterize substrate binding and enzyme kinetics for these therapeutically relevant kinases.
Main Methods:
- Enzyme kinetics assays using varying substrate concentrations (peptide and ATP).
- Inhibition studies with dead-end inhibitors, including PNU 112455A.
- Kinetic data analysis using nonlinear least squares and Lineweaver-Burk methods.
- X-ray crystallography to determine inhibitor binding mode.
Main Results:
- Both CDK2-cyclin E and CDK5-p25 were determined to follow a sequential random kinetic mechanism.
- Substrate binding was characterized by anticooperativity, where initial substrate binding reduces affinity for the second.
- Kinetic parameters (Km, anticooperativity factor alpha) were quantified for both enzyme systems.
Conclusions:
- The sequential random mechanism and anticooperative substrate binding are conserved features of CDK2-cyclin E and CDK5-p25.
- This mechanistic understanding provides a foundation for designing specific inhibitors for oncology and neurodegenerative diseases.
Related Concept Videos
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of CDK Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...


